Skip to main content
Bright Minds Biosciences Inc. logo

Bright Minds Biosciences Inc. — Investor Relations & Filings

Ticker · DRUG ISIN · CA10919W4056 CSE Professional, scientific and technical activities
Open in API
Filings indexed 198 across all filing types
Latest filing 2026-01-20 Regulatory Filings
Country CA Canada
Listing CSE DRUG

About Bright Minds Biosciences Inc.

https://brightmindsbio.com/

Bright Minds Biosciences Inc. is a biotechnology company specializing in the development of innovative therapeutics for neurological and psychiatric disorders, including severe and life-altering diseases such as epilepsy and Prader-Willi Syndrome. The company's scientific approach centers on healing the central nervous system and brain through the precise regulation of serotonin. Utilizing a proprietary chemistry platform, Bright Minds develops highly selective serotonin receptor agonists, specifically 5-HT2A and 5-HT2C agonists, designed to exclude 5-HT2B activity. This focus aims to create the next generation of serotonin-based drugs to address major challenges in mental health and neurology.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a formal notice sent to Canadian securities regulators detailing the logistics of an upcoming Annual General Meeting (AGM) (meeting type, record dates, location, Notice and Access requirements) rather than the AGM materials themselves or proxy solicitation to shareholders. It does not present financial results, voting results, or serve as the full meeting materials. This matches a general regulatory announcement/filing. Therefore, it is classified under Regulatory Filings (RNS).
2026-01-20 English
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Canadian securities Material Change Report filed on Form 51-102F3 under NI 51-102 (not an annual or interim financial report, nor an earnings press release, AGM presentation, or investor deck). It discloses two material events (Phase 2 trial topline results and a public offering under an underwriting agreement) as required by regulation. There is no broader management discussion and analysis or full financial statements, and it is not simply an announcement that a report is available. It is a statutory regulatory disclosure that does not fit into more specific categories, so it falls into the general Regulatory Filings category.
2026-01-09 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the pricing of a public offering of common stock (a capital raise). It details the number of shares, the price per share, the total proceeds, the underwriters involved, and the intended use of proceeds. This falls squarely under the definition of a Capital/Financing Update (CAP), as it describes a specific fundraising activity and changes to the company's capital structure, including the termination of an existing ATM program.
2026-01-08 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the launch of a US$100 million public offering of common shares and pre-funded warrants, detailing use of proceeds, underwriters, registration statements, and related financing terms. This is a corporate fundraising update rather than an earnings report, regulatory filing, or management discussion. Therefore, it falls under “Capital/Financing Update” (CAP).
2026-01-06 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a public offering of common shares and pre-funded warrants by Bright Minds Biosciences to raise US$100 million. It details the purpose of the offering (funding clinical trials), the underwriters involved, and references the filing of a registration statement with the SEC. This falls squarely under the definition of a capital/financing update, as it describes the company's fundraising activities and capital structure changes.
2026-01-06 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a short announcement (under 5,000 characters) notifying the public about an upcoming conference call and webcast to discuss clinical trial results. It does not contain the actual financial report or the transcript itself, but rather serves as an announcement of an event where information will be presented. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement or a general regulatory announcement regarding an event.
2026-01-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.